anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: neurology. SUBSTANCE: invention provides stable aqueous pharmaceutical compositions with human nerve growth factor, containing aqueous isotonic buffered solutions with pH values from about 4.5 to about 6.0 and optionally containing carrier such as human serum albumin. Also provided are aqueous compositions with human nerve growth factor appropriate for lyophilization and subsequent reduction, wherein nerve growth factor is mixed with sugars, optionally with human serum albumin, and with buffer. Compositions are effective in treatment of Alzheimer disease and other nervous disturbances. EFFECT: increased stability with regard to biological activity. 14 cl, 5 tbl, 9 ex
Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
Counselling sessions will be conducted at the designated centers operated by the Zubin foundation. According to the level of the DASS score, 6 to 10 sessions (based on the algorithm) of counselling service will be provided to the participants by three registered counsellors. A lead counsellor will oversee all cases and services. The counselling program consists of 6-10 60-minute sessions, and the sessions can be flexibly delivered over 1 to 2 weeks, ranging from one 60-minute session biweekly or weekly.
PURPOSE:To provide the subject compound having an inhibiting activity against serine protease, thiol protease, and especially proline endopeptidase and useful as an active ingredient for amnesia wedicines. CONSTITUTION:A compound of formula I (X is benzoyl, lower alkylcarbonyl, etc.; Y is lower alkyl, cycloalkyl, etc.,) or its salt, e.g. N-cyclohexyl-2- oxo-2-[2-(1-(benzoyl)pyrrolidinyl)]acetoamide. The compound is produced e.g. as follows; obtaining a compound of formula III from an N-benzyloxycarbonyl- proline of formula II (Z is benzyloxycarbonyl) by a known method, reacting the compound of formula III with the active derivative of an acid of X-OH and with the active ester of 1-hydroxybenzotriazole, reacting the reaction product with an amine of formula: NH2-Y and subsequently oxidizing the produced new intermediate of formula IV.
This study investigated the impact of resveratrol on abnormal metabolic remodeling in atrial fibrillation (AF) and explored potential molecular mechanisms. An AF cell model was established by high-frequency electrical stimulation of HL-1 atrial muscle cells. Resveratrol concentrations were optimized using CCK-8 and flow cytometry. AF-induced increases in ROS and mitochondrial calcium, along with decreased adenosine triphosphate (ATP) and mitochondrial membrane potential, were observed. Resveratrol mitigated these changes and maintained normal mitochondrial morphology. Moreover, resveratrol acted through the SIRT3-dependent pathway, as evidenced by its ability to suppress AF-induced acetylation of key metabolic enzymes. SIRT3 overexpression controls acetylation modifications, suggesting its regulatory role. In conclusion, resveratrol's SIRT3-dependent pathway intervenes in AF-induced mitochondrial dysfunction, presenting a potential therapeutic avenue for AF-related metabolic disorders. This study sheds light on the role of resveratrol in mitigating AF-induced mitochondrial remodeling and highlights its potential as a novel treatment for AF.
Caffeine and (mental) stress can increase blood pressure. In a typical everyday and/or work environment they commonly coincide. Tea has the reputation of being a relaxing drink. L-theanine is an amino acid found almost exclusively in tea. In a previous study it was shown that caffeine increased blood pressure, while theanine antagonised these effects. In the current study the effect of theanine to a placebo on blood pressure are directly compared.
Methods of stabilizing acidic cannabinoids by intercalating the acidic cannabinoids into layered double hydroxides (LFHs) are provided. Also provided are compositions comprising the LDH-intercalated acidic cannabinoids, physiologically compatible formulations comprising the compositions and methods of using the formulations to treat a variety of diseases and conditions in subjects.Methods of stabilizing acidic cannabinoids by intercalating the acidic cannabinoids into layered double hydroxides (LFHs) are provided. Also provided are compositions comprising the LDH-intercalated acidic cannabinoids, physiologically compatible formulations comprising the compositions and methods of using the formulations to treat a variety of diseases and conditions in subjects. Devices and methods for extracochlear stimulation are described herein. Such devices and methods may be configured for improving hearing in a subject in need thereof in any frequency range. In some embodiments, high frequency ranges are particularly targeted by the energy delivery elements provided herein. Low frequency ranges may be amplified by an acoustic amplifier, in various embodiments. Further, an external surface of the cochlea may be minimally prepared or altered prior to or during electrode placement on the cochlear surface. Such minimal preparation may include: disrupting mucosa on the external surface of the cochlea, applying an acid to the external surface of the cochlea, or applying a tissue growth factor to the external surface of the cochlea.
The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.
In the run-in part, up to two dose levels of capmatinib in combination with osimertinib were planned to be investigated. The initial dose level for the combination therapy was capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation was necessary, a lower dose level was defined as capmatinib 400 mg orally b.i.d and osimertinib 40 mg orally q.d.
Up to 200 patients will participate in an open, prospective and multi-center study.

Patients diagnosed as positive to COVID-19 will be referred to a VOQX examination. All patients will receive detailed explanation about the purpose of the examination, its impact and will provide their consent prior to the examination. The VOQX device output will have no influence on the decision-making process of the physicians and care givers. The VOQX Stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. The data collected in the form of breath sound signals in particular infra-sound will be transferred to an external computer and processed by machine learning algorithm developed by the company. The algorithm will seek patterns typical for the diagnosed disease for each corresponding case diagnosed.
Provided is a stable compound molecule that stays in the blood for a long period of time, a preparation method thereof, and applications thereof. Said compound molecule contains two nucleic acid chains X 1  and X 2  that are at least 80% complementary. The 5' end of X 1  and the 3' end of X 2  are linked by linking group L 1 , and/or, the 5' end of X 2  and the 3' end of X 1  are linked by linking group L 2 . In the present invention, the 5' ends and/or the 3' ends of the two nucleic acid chains, X 1  and X 2 , of the compound molecule are linked by a linking group as indicated in formula 1. The nucleic acid chain therefore is not easily untwisted and degraded, thereby enhancing the stability of a nucleic acid and extending the period of time that the nucleic acid stays in the blood. When the compound molecule is applied, nuclease present inside of cells is used to release the nucleic acid locked within the compound molecule. The double-stranded nucleic acid so released can then exert its function, such as siRNA's suppression of the expression of a target gene.
Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.
Group 1: 25 healthy lean men (age 30-45, BMI \<28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
Group 1 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. A subgroup of patients will receive an additional delirium screening using the CAM-PACU. This screening will be performed by another operator blinded for the results from the initial delirium screening.
The proposed study will be a randomized, controlled trial, conducted under Exception From Informed Consent (EFIC), comparing patients who undergo emergency tracheal intubation with one of two different endotracheal tubes (ETTs), one of which is designed to prevent ventilator-associated pneumonia (VAP): 1) An ETT fitted with a lumen to allow continuous aspiration of subglottic secretions and made with a polyurethane cuff (EVAC-PU-ETT); and 2) A standard ETT with a polyvinylchloride cuff (PVC-ETT). Approximately 1,074 adult patients requiring endotracheal intubation in the ED or hospital for acute respiratory distress or failure will be randomly assigned in an equal fashion to be intubated with one of the two ETTs (537 patients in each group). Because endotracheal intubation is performed in an emergency setting, the unit of randomization will be the intubation kits containing, in a concealed manner, one of the two types of ETT. The intubation kits are placed in areas where emergency intubation teams receive their intubation equipment supplies, primarily in the ICUs and in the emergency department. The study is designed to allow all patients requiring emergency intubation to be potentially eligible for enrollment to ensure the applicability of the study findings to a generalizable setting of patients receiving emergency intubation outside the operating room.

The trial primary aim is to determine if EVAC-PU-ETT is as safe as PVC-ETT and if long-term patient quality of life and cognitive function are better in PU-CASS-ETT, compared with PVC-ETT. The investigators will also monitor any device-related adverse events. Additional secondary endpoints include the incidence of infection-related ventilator associated conditions (IVAC) and ventilator associated events (VAEs), as defined by the Center for Disease Control, respiratory antibiotics use, incidence of "clinical" VAP, 28-day ventilator-free days, mean daily Sequential Organ Failure Assessment (SOFA) score, length of ICU and hospital stay, and mortality up to six months will serve to evaluate other clinical meaningful consequences resulting from the occurrence of VAP. Furthermore, the study will perform economic evaluation (cost-consequence approach) of quality of life, healthcare resource utilization and cost for hospitals. Primary and secondary endpoints will be compared between the PU-CASS-ETT and PVC-ETT groups, using an intention-to-treat approach.
In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
Tetralogy of Fallot (TOF) and double-outlet right ventricle (DORV) are conotruncal defects resulting from disturbances of the second heart field and the neural crest, which can occur as isolated malformations or as part of multiorgan syndromes. Their etiology is multifactorial and characterized by overlapping genetic causes. In this chapter, we present the different genetic alterations underlying the two diseases, which range from chromosomal abnormalities like aneuploidies and structural mutations to rare single nucleotide variations affecting distinct genes. For example, mutations in the cardiac transcription factors NKX2-5, GATA4, and HAND2 have been identified in isolated TOF cases, while mutations of TBX5 and 22q11 deletion, leading to haploinsufficiency of TBX1, cause Holt-Oram and DiGeorge syndrome, respectively. Moreover, genes involved in signaling pathways, laterality determination, and epigenetic mechanisms have also been found mutated in TOF and/or DORV patients. Finally, genome-wide association studies identified common single nucleotide polymorphisms associated with the risk for TOF.
The present invention relates to an oligomer or a poly-ylidene protein, a method and the application in the process of separating and purifying oligomer or poly-ylidene protein. The method can protect the activity of oligomer or poly-ylidene protein, and can improve yield. The oligomer protein or the poly-ylidene protein provides protein comprising more than two independent ylidenes polymerized by intermolecular force. The method comprises: a. protective agent of which the concentration is from 0.5 to 40% weight/volume is added in cell culture fluid, animal or plant tissue extract solution, or supernatant liquid after cell breakage, balanced solution and eluent solution at normal temperature; b. the method carries out cell breakage, membrane separation, adsorption or chromatographic separation and purification by conventional technology in order to obtain the oligomer protein or the poly-ylidene protein. The protein is applied in the process for preparing genetic engineering protein or vaccine. The method can effectively protect the integrity of protein molecular structures, reduce biological activity loss caused by separation and purification and improve target protein yield.
Herein are described methods of treating a human subject having acute myeloid leukemia (AML) that is refractory to induction therapy, wherein an MDM2 inhibitor is administered before or concurrently with chemotherapy, which may comprise induction therapy.  Refractory AML may be predicted based on decreased expression of MTF2 in cells from a hematological sample obtained from the subject. Also provided are methods of predicting and treating AML responsive to MDM2/HDM2 inhibitors, based on MTF2 expression.  One set of additional biomarkers useful in the predictions comprise one or more of H3K27me3, CD84, CD92, MDM2, NPM1, PRICKLE1, SET, ABCB6, POLQ, POLK, POLH, ARTIMIS, MCM6, CD327, CD90 and PARP1. Another set of additional biomarkers useful in the predictions include at least one of H3K27me3, MDM2, NPM1, SET, CD84 and PRICKLE1. Methods of selecting a patient for treatment with an MDM2 inhibitor before or concurrently with chemotherapy are also provided, along with kits and uses.
Sustained integration of evidence-based practices (EBPs) is a challenge within many healthcare systems, especially in settings that have already strived but failed to achieve longer-term goals. The Veterans Affairs (VA) Maintaining Implementation through Dynamic Adaptations (MIDAS) Quality Enhancement Research Initiative (QUERI) program was funded as a series of trials to test multi-component implementation strategies to sustain optimal use of EBPs. The current project focuses on increasing referrals to the Suicide Prevention 2.0 Clinical Telehealth (SP 2.0) initiative.

The investigators have recruited 4 sites for this non-randomized intervention project. Sites have agreed to participate in pre-implementation interviews to gather information regarding barriers and facilitators to use of the SP 2.0 initiative. Sites will then be provided with tailored feedback regarding interview findings and potential use of Academic Detailing and LEAP to address these. Sites may then select to receive either Academic Detailing and/or LEAP which will be provided by MIDAS QUERI. Primary outcome will be rate of SP 2.0 referral adjusted for pre-intervention rate.
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with alterations in genetic expression and epigenetic modifications. In recent years, the new insight into epigenetics in the pathogenesis of CLL has been developed considerably, including DNA methylation, histone modification, RNA methylation, non-coding RNAs as well as chromatin remodeling. Epigenetic modification regulates various processes such as stem cell biology, cell growth, and tumorigenesis without altering gene sequence. Growing evidence indicates that the disturbance of gene expression profiles which were regulated by epigenetic modifications exerts vital roles in the development and progress in CLL, which provides novel perspectives to explore the etiology of CLL. In addition, the integration with epigenetic therapeutic targets and the in-depth understanding of epigenetic therapy contribute to develop new therapeutic strategies for CLL. Herein, the present review discusses the advances of epigenetic alterations in the pathogenesis, diagnosis, and prognostic assessment of CLL patients and also highlights existing and emerging agents targeting epigenetic regulators.
The present invention provides implantable ocular drug delivery devices. Generally, the devices have a distal portion with a coil shaped body member and a proximal portion which contacts the sclera. In one aspect, the coil-shaped body member includes a unique configuration including two coiled portions with different pitches, which improves insertion of the device into the eye. In another aspect, the device has a proximal portion that includes a unique cap configuration having a concave distal face that improves stabilization of the device in the eye. In another aspect, the device includes a transitional portion between the cap and the coil-shaped body member that also improves stabilization of the device in the eye. The invention also provides methods for inserting the medical device into the eye, and methods for the treatment of an ocular condition.
<P>PROBLEM TO BE SOLVED: To make it possible to rapidly coat hair with a hair make-up agent to be coated on the hair.  <P>SOLUTION: A container for spray comprises aerosol cans having stems, an operation member with which the stems of the aerosol cans simultaneously are pressed down, and a spraying head having a nozzle for simultaneously spraying contents sprayed from the stems, wherein the aerosol can contain a hair dyeing composition arranged to have a viscosity of 1,000 to 100,000 cPs. A method for hair-dyeing work comprises wearing operation gloves, holding the spraying container, and then operating the operation member to spray the hair-dyeing composition from the nozzle. Therein, the hair-dyeing composition is directly received on a brush, and hair is then combed with the brush. Thus, the hair can rapidly be coated with the hair-dyeing composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
OBJECTIVES: Aging and excessive fat intake may additively induce dysbiosis of the gut microbiota and intestinal inflammatory damage. Here, we analyzed microbiota dysbiosis and intestinal injury in high-fat diet-loaded senescence-accelerated mice (SAMP8). Additionally, we examined whether treatment with molecular hydrogen could improve the intestinal environment.
METHODS: SAMP8 and SAMR1 (control) mice were first fed a normal diet (ND) or high-fat diet (HFD) for 10 wk (n = 10 each group). Subsequently, HFD was supplemented with a placebo jelly or hydrogen-rich jelly (HRJ) for 4 wk. After treatment, isolated small intestinal tissues were used for hematoxylin and eosin staining, immunofluorescence staining, and thiobarbituric acid reactive substances (TBARS) assay. Furthermore, we analyzed alterations in the microbiota composition in cecal feces using 16S rRNA gene analysis for microbiota profiling. Statistical analyses were performed using unpaired Student's t tests or one-way analysis of variance and Tukey's post hoc test for multiple comparisons.
RESULT: HFD feeding reduced the expression of caudal-related homeobox transcription factor 2 (CDX2) and 5-bromo-2'-deoxyuridine (BrdU) and enhanced malondialdehyde (MDA) levels in the small intestine of SAMP8. HRJ treatment improved the reduction in CDX2 and BrdU and enhanced MDA levels. We performed a sequence analysis of the gut microbiota at the genus level and identified 283 different bacterial genera from the 30 samples analyzed in the study. Among them, Parvibacter positively correlated with both HFD intake and aging, whereas 10 bacteria, including Anaerofustis, Anaerosporobacter, Butyricicoccus, and Ruminococcus were negatively correlated with both HFD and aging. HRJ treatment increased Lactinobactor and decreased Akkermansia, Gracilibacter, and Marvinbryantia abundance.
CONCLUSION: Our findings suggest that treatment with molecular hydrogen may affect microbiota profiling and suppress intestinal injury in HFD-loaded SAMP8.
The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death- 1 (PD-1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T- cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder. In a specific embodiment the isolated PD-1 antibody (H2M7798N) or binding fragment thereof which comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) having an amino acid sequence of SEQ ID NO: 162, and three light chain CDRs (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO: 170, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 164; HCDR2 comprises an amino acid sequence of SEQ ID NO: 166; HCDR3 comprises an amino acid sequence of SEQ ID NO: 168; LCDR1 comprises an amino acid sequence of SEQ ID NO: 172; LCDR2 comprises an amino acid sequence of SEQ ID NO: 174; and LCDR3 comprises an amino acid sequence of SEQ ID NO: 176. The antibody H2M7798N is associated with increased binding affinity for the PD-1 dimer and is associated with increased tumor killing abilities in vivo.